메뉴 건너뛰기




Volumn 116, Issue , 2016, Pages 41-48

Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD

Author keywords

Aclidinium; COPD; Formoterol; LABA; LAMA; Muscarinic antagonist

Indexed keywords

ACLIDINIUM BROMIDE PLUS FORMOTEROL FUMARATE; FORMOTEROL FUMARATE; ACLIDINIUM BROMIDE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; TROPANE DERIVATIVE;

EID: 84968627168     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2016.05.007     Document Type: Article
Times cited : (26)

References (25)
  • 2
    • 0022978869 scopus 로고
    • In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline
    • R.G. Goldie, D. Spina, P.J. Henry, K.M. Lulich, and J.W. Paterson In vitro responsiveness of human asthmatic bronchus to carbachol, histamine, beta-adrenoceptor agonists and theophylline Br. J. Clin. Pharmacol. 22 1986 669 676
    • (1986) Br. J. Clin. Pharmacol. , vol.22 , pp. 669-676
    • Goldie, R.G.1    Spina, D.2    Henry, P.J.3    Lulich, K.M.4    Paterson, J.W.5
  • 3
    • 34447120838 scopus 로고    scopus 로고
    • Reducing cholinergic constriction: The major reversible mechanism in COPD
    • V. Brusasco Reducing cholinergic constriction: the major reversible mechanism in COPD Eur. Respir. Rev. 15 2006 32 36
    • (2006) Eur. Respir. Rev. , vol.15 , pp. 32-36
    • Brusasco, V.1
  • 6
    • 84867119092 scopus 로고    scopus 로고
    • Efficacy and safety of twice-daily aclidinium bromide in COPD patients: The ATTAIN study
    • P.W. Jones, D. Singh, E.D. Bateman, A. Agusti, R. Lamarca, G. de Miquel, and et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study Eur. Respir. J. 40 2012 830 836
    • (2012) Eur. Respir. J. , vol.40 , pp. 830-836
    • Jones, P.W.1    Singh, D.2    Bateman, E.D.3    Agusti, A.4    Lamarca, R.5    De Miquel, G.6
  • 7
    • 84859305834 scopus 로고    scopus 로고
    • Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I)
    • E.M. Kerwin, A.D. D'Urzo, A.F. Gelb, H. Lakkis, E. Garcia Gil, C.F. Caracta, and et al. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I) COPD 9 2012 90 101
    • (2012) COPD , vol.9 , pp. 90-101
    • Kerwin, E.M.1    D'Urzo, A.D.2    Gelb, A.F.3    Lakkis, H.4    Garcia Gil, E.5    Caracta, C.F.6
  • 8
    • 84890299585 scopus 로고    scopus 로고
    • ACCORD COPD II: A randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients
    • S.I. Rennard, P.D. Scanlon, G.T. Ferguson, L. Rekeda, B.T. Maurer, E. Garcia Gil, and et al. ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients Clin. Drug Investig. 33 2013 893 904
    • (2013) Clin. Drug Investig. , vol.33 , pp. 893-904
    • Rennard, S.I.1    Scanlon, P.D.2    Ferguson, G.T.3    Rekeda, L.4    Maurer, B.T.5    Garcia Gil, E.6
  • 9
    • 37349061064 scopus 로고    scopus 로고
    • Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease
    • W.E. Berger, and J.A. Nadel Efficacy and safety of formoterol for the treatment of chronic obstructive pulmonary disease Respir. Med. 102 2008 173 188
    • (2008) Respir. Med. , vol.102 , pp. 173-188
    • Berger, W.E.1    Nadel, J.A.2
  • 12
    • 84965085606 scopus 로고    scopus 로고
    • Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: The 24-week, randomized, placebo-controlled AUGMENT COPD study
    • A.D. D'Urzo, S.I. Rennard, E.M. Kerwin, V. Mergel, A.R. Leselbaum, and C.F. Caracta Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study Respir. Res. 15 2014 123 141
    • (2014) Respir. Res. , vol.15 , pp. 123-141
    • D'Urzo, A.D.1    Rennard, S.I.2    Kerwin, E.M.3    Mergel, V.4    Leselbaum, A.R.5    Caracta, C.F.6
  • 13
    • 84921459850 scopus 로고    scopus 로고
    • Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): A multicentre, randomised study
    • D. Singh, P.W. Jones, E.D. Bateman, S. Korn, C. Serra, E. Molins, and et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study BMC Pulm. Med. 14 2014 178 189
    • (2014) BMC Pulm. Med. , vol.14 , pp. 178-189
    • Singh, D.1    Jones, P.W.2    Bateman, E.D.3    Korn, S.4    Serra, C.5    Molins, E.6
  • 15
    • 84926500092 scopus 로고    scopus 로고
    • Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4)
    • R. Buhl, F. Maltais, R. Abrahams, L. Bjermer, E. Derom, G. Ferguson, and et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2-4) Eur. Respir. J. 45 2015 969 979
    • (2015) Eur. Respir. J. , vol.45 , pp. 969-979
    • Buhl, R.1    Maltais, F.2    Abrahams, R.3    Bjermer, L.4    Derom, E.5    Ferguson, G.6
  • 16
    • 84904081919 scopus 로고    scopus 로고
    • Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: Results from a 52-week, randomized, double-blind, placebo-controlled study
    • J.F. Donohue, D. Niewoehner, J. Brooks, D. O'Dell, and A. Church Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study Respir. Res. 15 2014 78 88
    • (2014) Respir. Res. , vol.15 , pp. 78-88
    • Donohue, J.F.1    Niewoehner, D.2    Brooks, J.3    O'Dell, D.4    Church, A.5
  • 17
    • 77956338422 scopus 로고    scopus 로고
    • A one-year trial of tiotropium Respimat plus usual therapy in COPD patients
    • E.D. Bateman, D. Tashkin, N. Siafakas, R. Dahl, L. Towse, D. Massey, and et al. A one-year trial of tiotropium Respimat plus usual therapy in COPD patients Respir. Med. 104 2010 1460 1472
    • (2010) Respir. Med. , vol.104 , pp. 1460-1472
    • Bateman, E.D.1    Tashkin, D.2    Siafakas, N.3    Dahl, R.4    Towse, L.5    Massey, D.6
  • 18
    • 84868554172 scopus 로고    scopus 로고
    • Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: The GLOW2 study
    • E. Kerwin, J. Hébert, N. Gallagher, C. Martin, T. Overend, V.K. Alagappan, and et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study Eur. Respir. J. 40 2012 1106 1114
    • (2012) Eur. Respir. J. , vol.40 , pp. 1106-1114
    • Kerwin, E.1    Hébert, J.2    Gallagher, N.3    Martin, C.4    Overend, T.5    Alagappan, V.K.6
  • 19
    • 84896711038 scopus 로고    scopus 로고
    • Once daily glycopyrronium for the treatment of COPD: Pooled analysis of the GLOW1 and GLOW2 studies
    • A. D'Urzo, E. Kerwin, T. Overend, P. D'Andrea, H. Chen, and P. Goyal Once daily glycopyrronium for the treatment of COPD: pooled analysis of the GLOW1 and GLOW2 studies Curr. Med. Res. Opin. 30 2014 493 508
    • (2014) Curr. Med. Res. Opin. , vol.30 , pp. 493-508
    • D'Urzo, A.1    Kerwin, E.2    Overend, T.3    D'Andrea, P.4    Chen, H.5    Goyal, P.6
  • 20
    • 80052967109 scopus 로고    scopus 로고
    • Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients
    • D.P. Tashkin, S. Rennard, H.J. Taylor, D. Lawrence, J.P. Marton, and T.C. Lee Lung function and respiratory symptoms in a 1-year randomized smoking cessation trial of varenicline in COPD patients Respir. Med. 105 2011 1682 1690
    • (2011) Respir. Med. , vol.105 , pp. 1682-1690
    • Tashkin, D.P.1    Rennard, S.2    Taylor, H.J.3    Lawrence, D.4    Marton, J.P.5    Lee, T.C.6
  • 22
    • 84930615525 scopus 로고    scopus 로고
    • Pharmacological interaction between LABAs and LAMAs in the airways: Optimizing synergy
    • L. Calzetta, M.G. Matera, and M. Cazzola Pharmacological interaction between LABAs and LAMAs in the airways: optimizing synergy Eur. J. Pharmacol. 761 2015 168 173
    • (2015) Eur. J. Pharmacol. , vol.761 , pp. 168-173
    • Calzetta, L.1    Matera, M.G.2    Cazzola, M.3
  • 23
    • 26944440146 scopus 로고    scopus 로고
    • Distribution of receptor targets in the lung
    • P.J. Barnes Distribution of receptor targets in the lung Proc. Am. Thorac. Soc. 1 2004 345 351
    • (2004) Proc. Am. Thorac. Soc. , vol.1 , pp. 345-351
    • Barnes, P.J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.